云南医药2024,Vol.45Issue(6) :67-70.

结核合并慢性肾脏病抗结核治疗临床研究进展

Clinical research progress on anti-tuberculosis treatment for tuberculosis combined with chronic kidney disease

顾海霞 彭江丽 殷瑞 吴雪娇 陈洁 王璐
云南医药2024,Vol.45Issue(6) :67-70.

结核合并慢性肾脏病抗结核治疗临床研究进展

Clinical research progress on anti-tuberculosis treatment for tuberculosis combined with chronic kidney disease

顾海霞 1彭江丽 2殷瑞 1吴雪娇 1陈洁 2王璐2
扫码查看

作者信息

  • 1. 大理大学药学院,云南 大理 671000
  • 2. 昆明市第三人民医院/云南省传染性疾病临床医学中心药学部,云南 昆明 650041
  • 折叠

摘要

慢性肾脏病患者由于免疫功能低下以及肾功能受损导致感染结核的风险增加,而结核病患者中慢性肾脏病的患病率也明显增高,两病共存为临床的治疗带来了极大的困难.慢性肾脏病患者抗结核药物的选择和剂量调整非常重要,尤其是终末期GFR严重下降的结核患者抗结核药物剂量、频率、用药时间等的选择上需要结合2种疾病特点,考虑患者机体各方面的因素.本文总结了目前结核合并慢性肾脏病患者临床特征、治疗、预防、预后,为临床用药提供参考.

Abstract

Due to low immune function and impaired renal function,chronic kidney disease(CKD)patients have an increased risk of tuberculosis infection,and the prevalence of chronic kidney disease in tuberculosis patients has also increased significantly.The coexistence of the two diseases has brought great difficulties to clinical treatment.The selection and adjustment of the dose of anti-tuberculosis drugs in chronic kidney disease patients are very important,especially for tuberculosis patients with severe decline in GFR in the end stage,the selection of the dose,frequency,and duration of anti-tuberculosis drugs need to combine the characteristics of the two diseases,and consider various factors of the patient's body.This article summarizes the clinical characteristics,treatment,prevention and prognosis of patients with tuberculosis combined with chronic kidney disease,providing reference for clinical medication.

关键词

结核/慢性肾脏病/抗结核治疗/研究进展

Key words

tuberculosis/chronic kidney disease/anti-tuberculosis treatment/research progress

引用本文复制引用

出版年

2024
云南医药
中华医学会云南分会

云南医药

影响因子:0.459
ISSN:1006-4141
段落导航相关论文